申请人:Celltech Therapeutics Ltd.
公开号:US05891896A1
公开(公告)日:1999-04-06
Tri-substituted phenyl derivatives and pharmaceutical compositions containing them. In a preferred embodiment, the compounds have the general formula (2): ##STR1## wherein L is preferably --OR.sup.1 ; R.sup.a is preferably optionally substituted alkyl; R.sup.1 is preferably optionally substituted indanyl; R.sup.3 is preferably hydrogen, fluorine, hydroxy or an optionally substituted straight or branched chain alkyl group; R.sup.4 and R.sup.5 are preferably independently --(CH.sub.2).sub.t Ar, where t is zero or an integer 1, 2 or 3 wherein Ar is preferably optionally substituted monocyclic or bicyclic aryl or optionally substituted monocyclic or bicyclic heteroaryl; and R.sup.6 and R.sup.7 are preferably independently hydrogen, fluorine or optionally substituted alkyl. Compounds of the invention are potent and selective phosphodiesterase type IV inhibitors and are useful in the prophylaxis and treatment of various diseases, such as asthma, which are associated with an unwanted inflammatory response or muscular spasm.
三取代苯基衍生物及含有它们的药物组合物。在一个首选实施例中,这些化合物具有通用公式(2):其中 L 首选为 --OR^1;R^a 首选为可选取代的烷基;R^1 首选为可选取代的吲哚基;R^3 首选为氢、氟、羟基或可选取代的直链或支链烷基;R^4 和 R^5 首选独立为 --(CH_2)_t Ar,其中 t 为零或整数 1、2 或 3,其中 Ar 首选为可选取代的单环或双环芳基或可选取代的单环或双环杂芳基;R^6 和 R^7 首选独立为氢、氟或可选取代的烷基。本发明的化合物是有效且选择性磷酸二酯酶 IV 抑制剂,并可用于预防和治疗与不良炎症反应或肌肉痉挛相关的各种疾病,如哮喘。